Day: May 18, 2021

Frontline Ltd. (NYSE and OSE: FRO) (“Frontline” or the “Company”) today announces that it has entered into an agreement for the acquisition through resale of six latest generation ECO-type VLCC newbuilding contracts. The six VLCCs are currently under construction at the Hyundai Heavy Industries (“HHI”) shipyard in South Korea and are being acquired for an aggregate purchase price of $565.8 million, including an estimated $25.7 million in additions and upgrades to the standard specifications. The vessels are designed to operate on different fuels, including Biofuel, have the potential to be converted or retrofitted to consume fuel like LNG or Ammonia and consequently there is an ability to cut CO2 emissions to zero when technology, logistics and the regulatory framework allows for it. The newbuildings will also be fitted with Exhaust Gas...

PURCHASE, NY, May 18, 2021 (GLOBE NEWSWIRE) — Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, announced today that Jason Gorevic, chief executive officer, and Mala Murthy, chief financial officer, will participate in the William Blair Growth Stock Conference on June 1, 2021, at 1:40 p.m. ET. A live audio webcast and replay of the presentation will be available at http://ir.teladochealth.com/news-and-events/events-and-presentations/. About Teladoc HealthTeladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health...

Fourth quarter revenue increases 6% as reported; full year increases 3% as reported Full year earnings per diluted share of $4.63 on a U.S. GAAP basis and $6.17 on an adjusted basis on effective tax rates of 23.3% and 20.7%, respectively Company provides outlook for fiscal 2022 including Cantel MedicalDUBLIN, IRELAND, May 18, 2021 (GLOBE NEWSWIRE) — STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2021 fourth quarter ended March 31, 2021. Revenue as reported for the quarter increased 6% to $873.5 million compared with $823.0 million in the fourth quarter of fiscal 2020, with growth in all three segments. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 0.3% for the fourth quarter of fiscal 2021 as compared to constant currency organic revenue results...

SAN CARLOS, Calif., May 18, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced receipt of regulatory feedback from the U.S. Food and Drug Administration (FDA) regarding its potency assays for lifileucel. Previously, the company reported the submission of assay data to the FDA and recently the FDA provided comments regarding the data package. Following FDA feedback, Iovance will continue its ongoing work developing and validating its potency assays and plans to submit additional assay data and to meet with the FDA in the second half of 2021. The company’s biologics license application (BLA) submission for lifileucel is now expected to occur during the first half of 2022. “TIL is a first-in-class, one-time...

MONTREAL and SARASOTA, Fla., May 18, 2021 (GLOBE NEWSWIRE) — Intertape Polymer Group Inc. (TSX:ITP) (“IPG” or “the Company”) announced today the pricing of its offering of USD$400 million 4.375% senior unsecured notes due in 2029 (the “Offering”). These notes will be issued at par pursuant to a note indenture to be entered into with Regions Bank, as trustee, at the closing of the Offering. The Company anticipates that the closing of the Offering will occur on or about June 8, 2021. The Company intends to use the net proceeds from the Offering to redeem its currently outstanding USD$250 million 7.00% senior unsecured notes which are scheduled to mature on October 15, 2026 (the “Existing Notes”), to repay a portion of the borrowings outstanding under its existing five-year, USD$600 million credit facility...

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, May 18, 2021 (GLOBE NEWSWIRE) — Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) today announced its financial results for the three months ended March 31, 2021 (“Q1-2021”), posting income from mining operations of $5.3 million and a net income of $1.2 million. Fernando E. Ganoza, CEO and Director, commented, “This was a particularly challenging quarter given the operational setbacks resulting in loss production and an increase in cash cost, partially mitigated by higher realized metal prices leading to a cash margin of $2.38 per pound of payable copper. The Company closed the quarter showing a strong cash position of US$ 9.2 million and US$ 18 million in trade receivables, which were mostly realized in...

BOSTON, May 18, 2021 (GLOBE NEWSWIRE) — First Eagle Alternative Capital BDC, Inc. (NASDAQ: FCRD) (“First Eagle Alternative Capital BDC” or the “Company”) announced that it priced a public offering of $60,000,000 aggregate principal amount of 5.00% Notes due 2026 (the “Notes”). The Notes will mature on May 25, 2026 and may be redeemed in whole or in part at any time or from time to time at the Company’s option on or after May 25, 2023. The Notes will bear interest at a rate of 5.00% per year payable quarterly on March 30, June 30, September 30 and December 30 of each year, beginning September 30, 2021. The Company also granted the underwriters a 30-day option to purchase up to an additional $9,000,000 in aggregate principal amount of Notes to cover overallotments, if any. The Company expects to list the Notes on the New York Stock...

NEW YORK, May 18, 2021 (GLOBE NEWSWIRE) — Lexington Realty Trust (“Lexington”) (NYSE:LXP), a real estate investment trust focused on single-tenant industrial real estate investments, today announced that Elizabeth Noe has been appointed to its Board of Trustees and the Audit Committee of the Board of Trustees, effective May 18, 2021. Ms. Noe recently retired from the global law firm Paul Hastings LLP, which she joined in 1995.  She served as a partner in the firm from February 2001 and as Chair of the Corporate Department from February 2010 until February 2020.  Ms. Noe is the Vice-chair and Chair-elect of the Board of Trustees of Agnes Scott College and has served as a Trustee of the College since July 2014.  T. Wilson Eglin, Chairman, Chief Executive Officer and President of Lexington Realty Trust, commented, “We are delighted...

GARDEN CITY, N.Y., May 18, 2021 (GLOBE NEWSWIRE) — Lifetime Brands, Inc. (NasdaqGS: LCUT), a leading global designer, developer and marketer of a broad range of branded consumer products used in the home, today posted an updated investor presentation to its website, to be used in investor meetings beginning this week. The presentation can be accessed at https://lifetimebrands.gcs-web.com/events-and-presentations. The presentation highlights the Company’s successful execution of its “Lifetime Brands 2.0” growth strategy, strong recent performance and increased long-term growth targets. Lifetime Brands has provided revised five-year financial objectives, including the following forward-looking non-GAAP financial measures:Financial Measure 5-Year ObjectiveAdjusted EBITDA $120 million, revised from $90+ millionAdjusted EBITDA...

EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today announced that it will not continue ILLUMINATE-301, the Company’s trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, to its overall survival (OS) primary endpoint. The Company reported in March 2021 that the trial did not meet its primary endpoint of objective response rate (ORR). Full results from the study will be presented in a future publication. “Since receiving the disappointing ORR results from ILLUMINATE-301, we have interrogated the full data set and consulted with our study Steering Committee, our partners at Bristol Myers Squibb (BMS), and other stakeholders regarding next steps for the trial. Our conclusion is that the...